InfuSystem Holdings, Inc.

AMEX:INFU

Medical - Instruments & Supplies

Healthcare
$14.06 +4.00%

+$0.35 today

Market cap
$281.67M
Beta
1.42
P/E (TTM)
23.2
EPS (TTM)
$0.39
52W Low $5.38High $11.04

Volume 0.19M

Average 0.16M

Financial health

InfuSystem Holdings, Inc. financial health

Start with the overall verdict and the rule-based risk checks for INFU, then work through liquidity, debt, balance-sheet quality, and claims on cash.

Financial health snapshot

Mixed

The balance sheet looks mixed, so liquidity and debt trends deserve a closer read.

Debt exceeds cash and investments Healthy short-term liquidity Moderate leverage

Cash & Investments

$2.11M

Debt Cushion

-$20.66M

Current Ratio

2.1x

Interest Coverage

Not available

Risk checks

0 of 10 checks flagged

  • Positive equity

    Positive

    Passes when: Shareholders’ equity is above zero.

  • Interest coverage

    15.3×

    Passes when: Operating income is at least 1.5 times interest expense.

  • Short-term liquidity

    2.1×

    Passes when: Current assets are at least 1 times current liabilities.

  • Manageable net debt

    0.8×

    Passes when: Net debt is below 3 times EBITDA.

  • Debt repayment from cash flow

    1.1 yr

    Passes when: Free cash flow could repay all debt within 5 years.

  • Debt growth versus revenue growth

    -54.7% vs. 9.3%

    Passes when: Over three years, debt growth is no more than 5 percentage points above revenue growth.

  • Tangible equity base

    17.6%

    Passes when: Goodwill and intangibles are below 50% of equity.

  • Altman Z-score trend

    3.25 → 3.74

    Passes when: The Z-score is stable or rising, or stays above 2.99.

  • Stock-based compensation

    19.0%

    Passes when: Stock-based compensation is no more than 20% of operating cash flow.

  • Share dilution

    -0.6% per year

    Passes when: Diluted share count grows no more than 2% per year.

Financial strength scores

How strong are the fundamentals over time?

Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.

Financial strength scores

Piotroski F-Score and Altman Z-Score from the latest reported financials

Piotroski F-Score

Strong

9 / 9

Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.

Altman Z-Score

Safe zone

5.79

Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.

Score history

Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.

Piotroski: 8–9 strong, 4–7 average, 0–3 weak. Altman: above 2.99 safe, 1.81–2.99 grey, below 1.81 distress. Our calculation can differ slightly from the provider's current scores above.

Liquidity

Can it meet short-term obligations?

Check whether cash and current assets cover what falls due within a year without depending on fresh financing.

Cash & Equivalents

$2.11M

Q1 2026

3Y +43.0%1Y -33.9%

Quick Ratio

1.8x

Q1 2026

Current Ratio

2.1x

Q1 2026

Cash Ratio

0.1x

Q1 2026

Working capital

How quickly does cash come back?

Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.

Working capital and cash conversion

Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.

Working capital (Q1 2026)

$19.52M

Current assets − current liabilities

Days sales outstanding

58 d

+1 days vs. prior year

Days inventory outstanding

31 d

-6 days vs. prior year

Days payables outstanding

63 d

+7 days vs. prior year

Cash conversion cycle

27 d

-12 days vs. prior year

Leverage

How much debt risk sits on the balance sheet?

Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.

Total Debt

$22.77M

Q1 2026

3Y -9.2%1Y +564.3%

Debt/Equity

0.4x

Q1 2026

Debt/Assets

0.2x

Q1 2026

Interest Coverage

—

Q1 2026

Debt service

Can cash flow carry the debt?

Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.

Debt service capacity

Can operating cash flow carry the debt, and how much is due soon?

Net debt

$20.66M

Total debt − cash − short-term investments

Net debt / EBITDA

0.8×

Above 3× is elevated

Free cash flow / debt

89.2%

Share of debt one year of FCF could repay

Years to repay debt

1.1 yr

Total debt ÷ free cash flow

Operating cash flow / current liabilities

1.4×

Above 1× funds a year of obligations

Interest coverage

15.3×

Operating income ÷ interest expense

Debt maturity

Due within 12 months$0Due later$19.65M

Balance sheet as of Q1 2026; cash flows TTM to Q1 2026.

Debt and cash over time

Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.

Balance sheet cushion

How much room is there if conditions weaken?

Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.

Long-Term Investments

$0.00

Q1 2026

Assets

$98.66M

Q1 2026

3Y -0.7%1Y -1.9%

Liabilities

$39.91M

Q1 2026

3Y -4.8%1Y -7.7%

Balance sheet quality

Who funds the assets, and how tangible is the equity?

Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.

Balance sheet quality

Who funds the assets, and how much of the equity is tangible (Q1 2026).

Claims on $98.66M in assets

  • Payables9.8%
  • Long-term debt19.9%
  • Other liabilities10.8%
  • Equity59.5%

Goodwill + intangibles

$10.37M

10.5% of total assets

Share of equity

17.6%

Above 50% leaves little tangible backing

Tangible equity

$48.38M

Equity left after writing off goodwill and intangibles

Deferred revenue

$0

Customer prepayments: a liability settled by delivering service, not cash

Shareholder claims

What do shareholders take out of the cash?

Dilution, stock-based pay, dividends, and buybacks all draw on cash flow; check whether free cash flow funds them.

Shareholder claims on cash

Dilution, stock-based pay, and whether free cash flow funds what is returned to shareholders.

Diluted shares, yearly change

-0.6%

Compound annual rate from FY 2020 to FY 2025

Stock-based compensation

$4.49M

19.0% of operating cash flow

Dividends paid

None

TTM to Q1 2026

Dividend / free cash flow

—

Above 100% means dividends exceed free cash flow

Buybacks

$8.83M

TTM to Q1 2026

Weighted diluted shares outstanding

Competitor health

How does InfuSystem Holdings, Inc. compare with peers?

Compare leverage, interest coverage, and liquidity ratios with similar companies.

Competitor Health

Peer financial health comparison

CompanyMarket CapD/ED/AssetsND/EBITDAInt. Cov.QuickCurrentCash

ICU Medical, Inc.

ICUI:NASDAQ

$4.48B0.660.343.511.011.132.360.62

KORU Medical Systems, Inc.

KRMD:NASDAQ

$160.49M0.210.122.98—1.992.441.08

Questions

Financial health questions

Common questions about INFU's balance sheet, answered from the reported figures.

Is INFU's balance sheet healthy?

InfuSystem Holdings, Inc. (INFU) has a current ratio of 2.14, a quick read on short-term liquidity.

How leveraged is INFU?

Debt to equity is 0.39, which helps judge how much financing risk sits on the balance sheet.